Overview

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Status:
Completed

Trial end date:
2018-08-24

Target enrollment:

Participant gender:

Summary

This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Purdue Pharma LP

Treatments:

Lemborexant